aTyr Pharma Company Profile (NASDAQ:LIFE)

About aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma logoaTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:LIFE
  • CUSIP: 53217V10
  • Web: www.atyrpharma.com/
Capitalization:
  • Market Cap: $128.73 million
  • Outstanding Shares: 23,839,000
Average Prices:
  • 50 Day Moving Avg: $4.58
  • 200 Day Moving Avg: $4.58
  • 52 Week Range: $2.10 - $6.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.97
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.68 per share
  • Price / Book: 3.21
Profitability:
  • EBITDA: ($50,670,000.00)
  • Return on Equity: -107.31%
  • Return on Assets: -76.55%
Debt:
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 6.13%
  • Quick Ratio: 6.13%
Misc:
  • Average Volume: 167,620 shs.
  • Beta: 4.06
  • Short Ratio: 13.67
 

Frequently Asked Questions for aTyr Pharma (NASDAQ:LIFE)

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

How were aTyr Pharma's earnings last quarter?

aTyr Pharma Inc (NASDAQ:LIFE) issued its quarterly earnings results on Monday, August, 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.57) by $0.06. View aTyr Pharma's Earnings History.

When will aTyr Pharma make its next earnings announcement?

aTyr Pharma is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for aTyr Pharma.

Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2017?

4 analysts have issued 1 year price objectives for aTyr Pharma's stock. Their forecasts range from $2.85 to $7.00. On average, they anticipate aTyr Pharma's stock price to reach $4.46 in the next year. View Analyst Ratings for aTyr Pharma.

Who are some of aTyr Pharma's key competitors?

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the folowing people:

  • John K. Clarke, Independent Chairman of the Board
  • John D. Mendlein Ph.D., Chief Executive Officer, Director
  • John T. Blake, Senior Vice President - Finance
  • David John King Ph.D., Senior Vice President - Research
  • Grove Matsuoka, Senior Vice President, Product Programs and Planning
  • Ashraf Amanullah Ph.D., Vice President, Biologics Development and Manufacturing
  • Sanuj K. Ravindran M.D., Chief Business Officer
  • Sanjay S. Shukla M.D., Chief Medical Officer
  • Timothy P. Coughlin CPA, Director
  • Jeffrey S. Hatfield, Director

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

How do I buy aTyr Pharma stock?

Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is aTyr Pharma's stock price today?

One share of aTyr Pharma stock can currently be purchased for approximately $5.40.


MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  467
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for aTyr Pharma (NASDAQ:LIFE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $4.46 (17.36% downside)
Consensus Price Target History for aTyr Pharma (NASDAQ:LIFE)
Price Target History for aTyr Pharma (NASDAQ:LIFE)
Analysts' Ratings History for aTyr Pharma (NASDAQ:LIFE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/7/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$7.00HighView Rating Details
8/15/2017BMO Capital MarketsSet Price TargetHold$4.00HighView Rating Details
3/20/2017Citigroup Inc.Boost Price TargetNeutral$3.00 -> $4.00MediumView Rating Details
3/18/2017J P Morgan Chase & CoReiterated RatingHoldMediumView Rating Details
3/31/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for aTyr Pharma (NASDAQ:LIFE)
Earnings by Quarter for aTyr Pharma (NASDAQ:LIFE)
Earnings History by Quarter for aTyr Pharma (NASDAQ LIFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017N/AView Earnings Details
8/14/2017Q2 2017($0.57)($0.51)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.50)($0.56)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.67)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.71)($0.65)ViewN/AView Earnings Details
5/11/2016Q1($0.70)($0.68)ViewN/AView Earnings Details
3/30/2016Q4($0.52)($0.70)ViewN/AView Earnings Details
11/10/2015Q3($0.48)($0.48)ViewN/AView Earnings Details
8/12/2015Q215($0.53)($0.74)ViewN/AView Earnings Details
6/18/2015Q115($0.41)($0.38)ViewN/AView Earnings Details
11/5/2013Q313$0.97$1.02$926.10 million$936.00 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.96$0.72$952.06 million$944.00 millionViewN/AView Earnings Details
5/2/2013Q1 2013$1.04$1.07$958.56 million$963.00 millionViewN/AView Earnings Details
2/4/2013Q4 2012$1.11$1.11$988.85 million$998.90 millionViewN/AView Earnings Details
11/1/2012Q312$0.89$0.92$907.91 million$911.00 millionViewN/AView Earnings Details
7/31/2012$0.97$0.96ViewN/AView Earnings Details
2/7/2012$1.04$1.06ViewN/AView Earnings Details
10/25/2011$0.88$0.94ViewN/AView Earnings Details
7/28/2011$0.95$0.89ViewN/AView Earnings Details
4/26/2011$0.85$0.85ViewN/AView Earnings Details
2/3/2011$0.87$0.90ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for aTyr Pharma (NASDAQ:LIFE)
2017 EPS Consensus Estimate: ($2.08)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.50)($0.50)($0.50)
Q3 20171($0.53)($0.53)($0.53)
Q4 20171($0.56)($0.56)($0.56)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for aTyr Pharma (NASDAQ:LIFE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for aTyr Pharma (NASDAQ:LIFE)
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 46.66%
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)
Institutional Ownership by Quarter for aTyr Pharma (NASDAQ:LIFE)
Insider Trades by Quarter for aTyr Pharma (NASDAQ:LIFE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017John MendleinCEOBuy37,736$2.65$100,000.40View SEC Filing  
8/31/2017Paul SchimmelDirectorBuy94,336$2.65$249,990.40View SEC Filing  
4/24/2017John MendleinCEOBuy124$3.00$372.00View SEC Filing  
4/20/2017John MendleinCEOBuy2,552$3.00$7,656.00View SEC Filing  
12/21/2016Paul SchimmelDirectorBuy25,000$2.28$57,000.00View SEC Filing  
12/20/2016Ashraf AmanullahVPBuy11,000$2.25$24,750.00View SEC Filing  
12/19/2016John MendleinCEOBuy69,000$2.20$151,800.00View SEC Filing  
12/16/2016Paul SchimmelDirectorBuy50,000$2.48$124,000.00View SEC Filing  
5/11/2016Grove MatsuokaInsiderBuy12,412$3.04$37,732.48View SEC Filing  
4/14/2016Paul SchimmelDirectorBuy66,219$4.18$276,795.42View SEC Filing  
4/13/2016Paul SchimmelDirectorBuy9,835$3.85$37,864.75View SEC Filing  
4/12/2016Paul SchimmelDirectorBuy9,127$3.71$33,861.17View SEC Filing  
4/11/2016Paul SchimmelDirectorBuy32,659$3.57$116,592.63View SEC Filing  
4/8/2016Paul SchimmelDirectorBuy85,000$3.22$273,700.00View SEC Filing  
4/7/2016Paul SchimmelDirectorBuy40,000$3.19$127,600.00View SEC Filing  
4/6/2016Paul SchimmelDirectorBuy25,000$3.20$80,000.00View SEC Filing  
4/5/2016John MendleinCEOBuy2,500$3.55$8,875.00View SEC Filing  
4/5/2016Paul SchimmelDirectorBuy25,000$3.52$88,000.00View SEC Filing  
5/12/2015James E FlynnInsiderBuy50,000$14.00$700,000.00View SEC Filing  
5/12/2015Sofinnova Venture Partners Ix,Major ShareholderBuy320,000$14.00$4,480,000.00View SEC Filing  
5/29/2013David C UprichardDirectorSell2,010$74.04$148,820.40View SEC Filing  
5/28/2013John A CottinghamInsiderSell60,000$74.03$4,441,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for aTyr Pharma (NASDAQ:LIFE)
Latest Headlines for aTyr Pharma (NASDAQ:LIFE)
Source:
DateHeadline
americanbankingnews.com logoaTyr Pharma, Inc. (LIFE) Expected to Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - October 7 at 6:26 PM
finance.yahoo.com logoHow Should You Think About aTyr Pharma Inc’s (LIFE) Risks?
finance.yahoo.com - October 5 at 8:18 AM
americanbankingnews.com logoaTyr Pharma, Inc. (LIFE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - October 2 at 4:32 AM
streetinsider.com logoaTyr Pharma (LIFE) to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset ... - StreetInsider.com
www.streetinsider.com - September 29 at 1:58 PM
finance.yahoo.com logoaTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society
finance.yahoo.com - September 27 at 10:14 AM
americanbankingnews.com logo Brokerages Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.53 EPS
www.americanbankingnews.com - September 19 at 12:26 AM
americanbankingnews.com logoPiper Jaffray Companies Begins Coverage on aTyr Pharma, Inc. (LIFE)
www.americanbankingnews.com - September 10 at 10:14 AM
finance.yahoo.com logoaTyr Pharma to Present at Two Upcoming Investor Conferences in September
finance.yahoo.com - September 6 at 2:03 AM
americanbankingnews.com logoInsider Buying: aTyr Pharma, Inc. (LIFE) CEO Buys 37,736 Shares of Stock
www.americanbankingnews.com - September 5 at 10:27 PM
americanbankingnews.com logoInsider Buying: aTyr Pharma, Inc. (LIFE) Director Buys 94,336 Shares of Stock
www.americanbankingnews.com - September 5 at 10:26 PM
streetinsider.com logoaTyr Pharma (LIFE) Reports $45M Private Placement
www.streetinsider.com - August 29 at 1:07 AM
finance.yahoo.com logoaTyr Pharma Announces $45 Million Equity Financing
finance.yahoo.com - August 28 at 8:05 PM
finance.yahoo.com logo[$$] Publicly Traded Rare Disease Drug-Maker aTyr Pharma Gets $46 Million Lift
finance.yahoo.com - August 28 at 8:05 PM
americanbankingnews.com logoWilliam Blair Analysts Lift Earnings Estimates for aTyr Pharma, Inc. (LIFE)
www.americanbankingnews.com - August 17 at 8:22 AM
americanbankingnews.com logoaTyr Pharma, Inc. (LIFE) Releases Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - August 15 at 2:38 PM
americanbankingnews.com logoaTyr Pharma, Inc. (LIFE) Given "Hold" Rating at BMO Capital Markets
www.americanbankingnews.com - August 15 at 1:06 PM
finance.yahoo.com logoaTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
finance.yahoo.com - August 15 at 1:02 AM
finance.yahoo.com logoAtyr Pharma reports 2Q loss
finance.yahoo.com - August 15 at 1:02 AM
americanbankingnews.com logoaTyr Pharma, Inc. (NASDAQ:LIFE) Expected to Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - August 13 at 2:24 AM
finance.yahoo.com logoaTyr Pharma Announces Date of Earnings Release For Second Quarter 2017 Financial Results
finance.yahoo.com - August 11 at 6:08 AM
americanbankingnews.com logoaTyr Pharma, Inc. (NASDAQ:LIFE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
News IconUPDATE 1-Contract medical research firm INC to buy inVentiv in $4.6 bln deal
www.businessinsider.com - May 11 at 11:47 PM
cnbc.com logoContract medical research firm INC to buy inVentiv in $4.6 billion deal
www.cnbc.com - May 11 at 11:47 PM
streetinsider.com logoaTyr Pharma (LIFE) Reports Top-Line Results from Resolaris Phase 1b/2 Trial
www.streetinsider.com - April 24 at 7:23 PM
biz.yahoo.com logoATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - April 4 at 8:02 AM
bizjournals.com logoaTyr Pharma Announces Fourth Quarter and Year-End 2016 Operating Results
www.bizjournals.com - March 16 at 7:04 PM
biz.yahoo.com logoATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 7:04 PM
baystreet.ca logoaTyr Pharma (LIFE) Gains on Orphan Drug Designation
www.baystreet.ca - March 3 at 11:14 PM
us.rd.yahoo.com logoaTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy with Resolaris™
us.rd.yahoo.com - March 3 at 6:13 PM
us.rd.yahoo.com logo8:01 am aTyr Pharma announces that the European Medicines Agency has granted orphan drug designation to Resolaris for the treatment of limb girdle muscular dystrophy patients
us.rd.yahoo.com - March 3 at 6:13 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Target, Frontier, aTyr Pharma, Intelsat - Nasdaq
www.nasdaq.com - March 2 at 10:18 AM
streetinsider.com logoaTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris - StreetInsider.com
www.streetinsider.com - March 2 at 10:18 AM
investopedia.com logoaTyr Pharma Rises 16% on Orphan Drug Status (LIFE)
www.investopedia.com - March 1 at 5:58 PM
investopedia.com logoaTyr Pharma Rises 16% on Orphan Drug Status
www.investopedia.com - March 1 at 5:58 PM
baystreet.ca logoaTyr Pharma (LIFE) Spikes on FDA Nod
www.baystreet.ca - February 28 at 6:24 PM
streetinsider.com logoaTyr Pharma (LIFE) Receives FDA Orphan Drug Designation for Treatment of LGMD with Resolaris
www.streetinsider.com - February 28 at 6:24 PM
investopedia.com logoAtyr Pharma Spikes 33% on FDA Update (LIFE)
www.investopedia.com - January 20 at 1:06 AM
investopedia.com logoAtyr Pharma Stock Spikes 33% on FDA Updates
www.investopedia.com - January 19 at 8:04 PM
streetinsider.com logoaTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status - StreetInsider.com
www.streetinsider.com - January 19 at 4:52 AM
finanznachrichten.de logoGainers & Losers Of The Day: APRI, LIFE, JAZZ, ETRM, BIOC...
www.finanznachrichten.de - January 18 at 11:50 PM
streetinsider.com logoaTyr Pharma (LIFE) Resolaris Gains FDA Fast Track Status
www.streetinsider.com - January 18 at 6:49 PM
us.rd.yahoo.com logoFDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris
us.rd.yahoo.com - January 18 at 6:49 PM

Social

Chart

aTyr Pharma (LIFE) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.